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Efficacy of Oral Diltiazem to Control Ventricular Response in Chronic
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LESLIE A. BUFF, RN, P. JACOB VARGHESE, MD, FACC
Washington. D.C.
Although digpxin is often the first choice for control of
ventricular response in chronic atrial fibrillation, it fails
to slow exercise rates. Diltiazem, a calcium channel an-
tagonist that slows atrioventricular conduction, was ad-
ministered to 16 patients who failed to achieve adequate
rate control on low level exercise testing despite digoxin
therapy. Therapeutic response to diltiazem was assessed
with submaximal and maximal exercise tests and 24 hour
ambulatory electrocardiographic monitoring.
During the diltiazem treatment phase, ventricular re-
sponse at rest diminished (96 ± 17 versus 69 ± 10
beats/min, p < 0.001) as did rate during submaximal
exercise (155 ± 28 versus 116 ± 26, P < 0.001), maxlmal
exercise (163 ± 14 versus 133 ± 26, P < 0.001) and
average ventricular response during 24 hour monitoring
Control of the ventricular response is the primary goal in
the treatment of chronic atrial fibrillation. Traditionally,
digitalis glycosides have been the pharmacologic agents of
first choice to modulate ventricular response in this setting.
Though digoxin often can control heart rate at rest, it affords
little, if any, protection against rapid rates during exercise
(1-10). Beta-adrenergic blocking agents may be useful sup-
plements to digoxin therapy (2,8,9); however, they have
several important contraindications and actually may di-
minish exercise capacity (2,10).
Conduction through the atrioventricular (AV) node is
mediated by the calcium-dependent slow channel. Calcium
channel antagonists prolong AV node conduction and re-
fractoriness (11-14), and have proved useful in the treat-
ment of supraventricular tachycardias that utilize the AV
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(87 ± 13 versus 69 ± 10, P < 0.001). Rate at rest
decreased 26 ± 15% and submaximal exercise rate di-
minished 24 ± 12%. Thirteen (81%) of the 16 patients
exhibited at least 15% slowing of rate at rest and during
submaximal exercise. Eleven patients (69%) reported
alleviation of symptoms. There was no change in serum
digoxin levels during diltiazem treatment (1.3 ± 0.5
versus 1.3 ± 0.6 ng/ml, p = NS). On withdrawal of
diltiazem, ventricular response returned to baseline val-
ues.
Diltiazem is an effective agent for control of ventric-
ular response, both at rest and during exercise, in di-
goxin-treated patients with chronic atrial fibrillation.
(J Am Coil CardioI1987;9:40S-11)
node. In multiple studies, verapamil has been shown to
terminate AV node reentrant tachycardia (15,16) as well as
decrease both the rest and exercise ventricular response in
atrial fibrillation (1,4-7,17). Diltiazem has electrophysio-
logic properties similar to those of verapamil (II , 14,18, 19)
and has been documented to prevent the induction of AV
node reentry (20-22).
It was our goal to determine the value of diltiazem to
impede AV conduction in patients with chronic atrial fi-
brillation. Thus. control of ventricular response was as-
sessed at rest .. during controlled exercise and during daily
activities.
Methods
Study patients (Table 1). Nineteen patients with chronic
atrial fibrillation were enrolled in the study and 16 completed
the entire study protocol. Eleven were men and five Were
women. The mean age was 66 ± 12 years (range 38 to
79). The study entry criterion required a ventricular response
rate greater than 100 beats/min at the completion of a limited
standardized exercise test (3 minutes, 3 miles/h, 0° grade).
Digoxin was continued if it had previously been part of the
0735-1097/87/$3.50
406 STEINBERG ET AL.
DILTIAZEM FORATRIAL FIBRILLATION
lACC Vol. 9. No.2
February 1987:405-11
Table 1. Clinical Characteristics of 16 Patients
Age (yr) CV Digoxin Dose Other CV
Patient &Sex Diagnosis (mg/day) Medication
I 79M CAD,HTN Diuretic, nitrate
2 75M LAF 0.125
3 56M LAF 0.25
4 58M LAF 0.5
5 74M LAF 0.25
6 73M CAD,HTN 0.125 Nitrate
7 76F LAF 0.25
8 75F HTN 0.25 Diuretic, prazosin
9 50M MVR 0.25 Diuretic, warfarin
10 70M DM, HTN
II 17M LAF 0.25
12 58F MVR, HTN 0.25 Diuretic, warfarin,
prazosin
13 59M CM, CHF 0.25 Nitrate. diuretic,
captopril,
warfarin
14 58F MS 0.25/0.375* Diuretic. nitrate,
warfarin
15 12M CAD,CHF Diuretic
16 38M MS 0.25 Diuretic, warfarin
*Altemate day dosages. AF = lone atrial fibrillation; CAD = coronary artery disease; CHF = congestive
heart failure; CM = idiopathic cardiomyopathy; CV = cardiovascular; DM = diabetes mellitus; HTN =
hypertension; MS = mitral stenosis; MVR = mitral valve replacement.
Phase
patient's medical regimen. For those taking digoxin, the
digoxin dose was adjusted to maintain a serum level in the
therapeutic range (0.5 to 2.0 ng/ml) before entry into the
formal study. Once this dosage was determined, digoxin
was continued throughout the study without adjustment. All
but three patients were on long-term digoxin therapy. All
other antiarrhythmic medications including beta-adrenergic
blockers, calcium channel blockers and class 1 antiarrhyth-
mic agents were discontinued at least five half-lives before
the start of the formal study.
Exclusion criteria were recent use of an investigational
drug, unstable angina or acute myocardial infarction, Wolff-
Parkinson-White syndrome, clinically significant renal or
hepatic failure, sick sinus syndrome without a functioning
pacemaker, uncontrolled hypertension, systolic blood pres-
sure less than 95 mm Hg, cardiac or other diseases that
prevented upright exercise, or a history of untoward reaction
to diltiazem. A history of congestive heart failure was not
a contraindication to participation.
All patients gave informed consent before participation
in the study. The study protocol was approved by the Human
Investigation Committee at this institution.
Study design. The study was divided into three open
label phases (Fig. I). The initial phase served as a baseline
period to allow recording of baseline variables after the
digoxin dose had been adjusted. The second phase involved
the administration of diltiazem (Cardizem) and observation
of its effect on specific variables. In the final phase diltiazem
was withdrawn to provide a comparison period and to ac-
count for the effects of training (23). Phases occurred as 3
consecutive I week periods.
During the baseline pretreatment phase 1, a history and
physical examination were performed followed by a 12 lead
electrocardiogram, submaximal exercise treadmill test (3
minutes, 3 miles/h, 0° grade) and 24 hour ambulatory mon-
itoring (Cardiodata MK3 system with analysis at George
Washington University). Heart rate at rest was measured
with the patient supine. Ventricular response and blood pres-
sure were monitored at I minute intervals during and for 3
minutes after exercise testing. Ventricular response was
counted over at least 20 seconds at I minute intervals.
Figure 1. Study design. + = optional high dose phase if the 3
minute submaximal exercise heart rate was still greater than 135
beats/min. OIL = diltiazem; ECG = electrocardiogram; ETT =
exercise treadmill test.
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The patient then entered phase 2 and was treated with
diltiazem, 60 mg four times daily. After 7 days a repeat
examination including a 3 minute submaximal exercise test
and 24 hour monitoring was performed. If peak exercise
ventricular response was still greater than 135 beats/min,
the diltiazem dose was increased to 90 mg four times daily
and repeat testing was performed after an additional week
of study. At the completion of phase 2 on maximal dose
diltiazem therapy (60 or 90 mg four times daily) all patients
underwenta symptom-limited (maximal) exercise test using
a Bruce or modified Bruce protocol. This followed the :3
minute exercise test by a 15 minute rest period.
Patients entered phase 3 after testing on treatment with
the optimal diltiazem dose. Diltiazem was discontinued for
7 days whereon a complete examination was performed,
includingsubmaximal (3 minute)and maximal exercise tests
and 24 hour ambulatory monitor.
Digoxin serum levels were determined immediately be-
fore exercise at each visit and diltiazem levels by high pres-
sure liquid chromatography at visits during phase 2. All
exercise tests were performed 2 to 5 hours after the diltiazem
dose was administered when diltiazem levels would be ex-
pected to achieve their peak concentration (18). Careful
observation for and documentation of adverse effects were
made.
Analysis of data. Results are presented as mean ± SO.
Statistical analysis was performed using the Student's t test
for paired and unpaired data.
Results
Nineteen patients met the criteria for entry into the study.
but the study was terminated prematurely in three of them:
• Pre-d' " zem p<.OO P<.OO
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Figure2. Rest and exercise ventricular response with and without
diltiazem treatment. Data are presented as mean values ± SO.
BPM = beats per minute.
one withdrew voluntarily without explanation and two de-
veloped intolerable side effects within 3 days of diltiazem
therapy. The remaining 16 patients constituted the diltiazem
study group listed inTable I. Results during active treatment
(phase 2) are reported for the optimal (maximal) diltiazem
dose: 60 mg four times daily in II patients and 90 mg four
times daily in 4 patients; I patient was studied at 30 mg
four times daily because of adverse effects at a greater dose
(see later).
Control of ventricular response. Therapy with dilti-
azem resulted in significant reductions in various rest and
exercise variables (Table 2, Fig. 2). Ventricular response
was reduced at rest, at all levels of submaximal exercise
and at conclusion of the maximal exercise evaluation. Rest
ventricular rate dropped 26 ± 15% and 3 minute submax-
imal exercise ventricular rate diminished 24 ± 12%. Thir-
Table 2. Comparative Data Before and During Diltiazem Therapy in 16 Patients
Baseline Diltiazem p Value
Ventricular response (bea ts/mi n)
At rest 96 ± 17 69 ± 10 < 0. 00 1
I Minute ex (subrnaxirnal ETT) 145 ± 25 104 ::':: 21 < 0.00 1
2 Minu tes ex (subrnaximal ETT ) 152 ± 26 110 ::':: 22 < 0.00 1
3 Minutes ex (submaxi rnal ETT) 155 ± 2X 116 ± 26 < 0.00 1
Peak ex (maxi mal ETT) 163 ± 14 LH ± 26 < 0.00 1
Average 24 hour X7 ± 13 69 ± 10 < 0 ,00 1
Maxim al 24 hour IX4 ± 24 14X ± 26 < 0 ,00 1
Minimal 24 hour 51 ± 7 41 ± 9 < 0.00 1
Hemodynamics
sBP. rest 136 ± 30 131 ± 21 NS
dBP , rest lD ± 14 72 ± 20 < 0. 0 1
sBP. 3 Minutes ex 160 ± 35 14X ± 26 NS
(submaximal ETT)
dBP . 3 Minutes ex XO ± 14 71) ± 9 NS
(subrnaxirnal ETT )
RPP . 3 Minutes ex 25.4 .U := 9.015 17.43 1 ± 5.3 1!! < 0.00 1
(submaxi mal ETT)
BP = blood pressure (rnrn Hg); dBP = diastolic blood pressure: ETf = exercise treadmill test: RPP =
rate-pressure product; sBP = systolic blood pressure ,
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Pre-diltiazem Diltiazem
Figure 4. Comparison of "slow" (pretreatment rate ::s 90 beats/min
at rest) (dashed line) and "fast" (pretreatment rate> 90 beats/min
at rest) (solid line) subgroups beforeand duringdiltiazemtherapy.
Data are presented as mean values ± SO. BPM = beats per
minute.
heart rate-systolic pressure product at maximal levels of
exertion decreased significantly during diltiazem therapy,
primarily because of a blunted rate response.
Maintenance serum diltiazem levels. The mean serum
diltiazem level at maximal dosage was 234 ± 187 ng/rnl.
Diltiazem level correlated only with the percent change in
heart rate at rest (r = 0.55, P < 0.05).
Diltiazem interaction with digoxin. The serum level
of digoxin in the 13 patients receiving digoxin before the
start of therapy was 1.3 ± 0.5 ng/m!. During diltiazem
therapy, the level was 1.3 ± 0.6 ng/ml (p = NS).
Symptomatic response. Eleven (69%) of the 16 patients
in the study group had subjective alleviation of symptoms
of fatigue, palpitation and breathlessness during the dilti-
azem treatment period. Four patients showed no improve-
ment and one patient had slight worsening of symptoms.
Adverse effects. Two patients developed severe dizzi-
ness necessitating diltiazem discontinuation before exercise
evaluation on treatment. Two patients developed an ery-
thematous rash; however, medication could be continued to
study completion. One patient experienced mild dizziness
shortly after diltiazem administration and one described nau-
sea only if diltiazem was not taken with meals. One study
subject had mild transient edema. Another patient developed
nausea, headache and edema while receiving diltiazem, 60
mg four times daily, and symptoms completely resolved
when the dose was reduced to 30 mg four times daily. Four
of the eight patients were older than 70 years or receiving
360 mg of diltiazem daily.
The one patient with preexistent congestive heart failure
and chronic ventricular ectopic rhythm manifested sustained
(40 seconds) ventricular tachycardia at a rate of 130/min
during the second minute of the submaximal exercise test
while receiving diltiazem, 60/mg. The episode was asymp-
tomatic, without observed hemodynamic changes and was
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Figure 3. Ventricular responserecordedwith 24 hour ambulatory
electrocardiographic monitoring before and during the diltiazem
treatment period. Results are the average 24 hour rate and the
maximal and minimalrates recordedduringthe monitoring period.
Data presentedas mean values ± SO. BPM = beats per minute.
teen (81%) of the 16 patients exhibited at least 15% slowing
of rate at rest and at 3 minutes of exercise.
Results during 24 hour ambulatory electrocardiographic
monitoring showed a similar significant reduction in average
ventricular response (Fig. 3). The mean 24 hour ventricular
rate declined 20 ± 8% and 13 patients (81%) achieved at
least a 15% rate reduction. Minimal and maximal rates
during long-term recording also demonstrated a significant
decline.
Statistical analysis revealed that diltiazem effect during
phase 2 was similar to that of both the predrug baseline
period (phase 1) and the postdrug withdrawal period (phase
3). Phase I and phase 3 results were comparable.
Comparison of "slow" and "fast" groups. The total
group was subclassified into patients whose pretreatment
rest ventricular rate was "fast" (90 beats/min; nine patients)
and those whose rate was "slow" (~ 90 beats/min; seven
patients). Those in the fast group had a 32 ± 17% reduction
in rest ventricular response from 107 ± 14 to 70 ± 13
beats/min and those in the slow group had an 18 ± 6%
reduction from 82 ± 8 to 68 ± 6 beats/min (Fig. 4). Percent
rate reduction was significantly greater in the fast group
(p < 0.05). Final rates at rest during treatment were not
significantly different between these subgroups.
Exercise capacity. When comparing diltiazem and post-
diltiazem maximal treadmill tests, there was no significant
improvement in peak exercise level (metabolic equivalents
[METS]) during active drug therapy (7.3 ± 2.4 METS in
phase 2 versus 7.0 ± 2.3 in phase 3). In six patients (38%)
exercise capacity improved by at least I MET during dil-
tiazem therapy. These patients with exercise improvement
were either younger «70 years old) or had underlying
mitral valve disease.
Effect on blood pressure. During diltiazem treatment,
diastolic blood pressure at rest fell slightly (Table 2). The
lACC Vol. 9. NO. 2
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self-terminating. Exerci se before diltiazem during treatment
with digoxin alone had revealed no ventricular tachycardia;
however , baseline 24 hour Holter monitoring demon strated
frequent and complex ventricular ectopic activity . After dis-
continuation of diltiazem and institution of specific antiar-
rhythmic therapy, repeat exercise stud ies revealed no ven-
tricular tachycardia. No change in ventricular ectopic activity
during diltiazem was noted in the other 15 patients .
There were no episodes of symptomatic bradycardia or
regularization of rhythm during the period of diltiazem ther-
apy . Hypotension did not occur in any patient and there
were no episodes of orthostatic hypoten sion .
Discussion
Limitation of digoxin therapy. Digoxin therapy for rate
control in atrial fibrillation is well entrenched in the tradition
of cardiovascular medicine. Whereas digoxin has modest
succes s in reducing rest ventricular response in atrial fi-
brillation, it has failed to prevent excessive tachycardia dur-
ing exertion (1-10). Our study clearl y confirms these ob-
servations. In the baseline phase, submaximal exercise quickly
produ ced ventricular rates above 150beats/min despite ther-
apeutic digoxin levels . Others (5,8 ) have demonstrated that
increa sing digoxin doses to achieve levels in the upper ther-
apeutic range also fails to significantly blunt exercise tachy -
cardia. The explanation for these findings resides in di-
goxin ' s mechanism of action in chronic atrial fibrillation.
Rate control by digoxin is primarly effected by cholinergic
potentiation . During stress or exerci se, parasympathetic ac-
tivity is overwhelmed by sympathetic discharges, thus ne-
gating digoxin's minimal autonomic effects .
Effects of beta-adrenergic blockade. Given the sym-
pathetic effects on AV node function, it is logical to assume
that beta-adrenergic blockade would be useful and, indeed,
rest and exercise rate control has been achieved with this
class of drugs (2,8,9). Beta-blockers, however, are limited
by their well known side effects and often result in reduced
exercise capac ity despite rate slowing. In one study (2) of
nadolol in atrial fibrillation , 65% of the patients had a sig-
nificant decrement in exercise time on beta-blocker therap y.
A small group of propranolol-treated patients showed either
no improvement or worsening of exerc ise tolerance (10) .
Calcium channel blockade as alternative therapy. De-
polarization of AV node tissue is a calcium-dependent pro-
cess by way of the slow channel. Calcium channel blockade
with verapamil depresses AV node action potential ampli-
tude and lengthens nodal refractoriness ( 14,24). The effect s
of verapamil on the electrical properties of the AV node are
independ ent of autonomic influences (24,25) and continue
to modulate AV conduction during exercise (26). Oral ve-
rapamil therapy for chronic atrial fibrillation augments rate
control in digitalized patients (1,4,6,7), and can be satis-
factory as monotherapy without concomitant digoxin (5).
Mean ventricular rate by 24 hour electrocardiographic mon-
itoring is slowed (7,17) and exercise rates are significantly
reduced (I ,4-7).
While oral verapamil exhibits efficacy in atrial fibrilla-
tion , definite limitations to its widespread use exist (27)
including its negative inotropic properties (28,29), elevation
of serum digoxin levels (30-32), delayed drug accumulation
(33) and emergence of accelerated junctional rhythm (34,35).
Efficacy of diltiazem for rate control in atrial fibril-
lation. Diltiazem shares with verapamil a potent negative
dromotropic effect without significant negative inotropic ef-
fects (36- 39). Mitchell et al. (40) found that diltiazem pro-
longed the atrial-His interval by 12% in sinus rhythm and
by 22% in constant paced rhythm. Nodal functional refrac-
tory period lengthened 6%, nodal effective refractory period
16% and Wenckebach cycle length 13% in the same study
(40) . Others (11,14,18,19) have found similar AV node
conduction delay and prolongation of refractoriness. These
electrophysiologic properties, similar to but less potent than
those of verapamil , make diltiazem potentially useful in the
treatment of supraventricular tachycardias . Intravenous dil-
tiazem was effective in the short-term management of par-
oxysmal supraventricular tachycardia (AV node reentry with
and without retrograde conduction in an accessory pathway)
(20, 21). Oral diltiazem succe ssfully prevented induction of
paroxysmal supraventricular tachycardia and during the fol-
low-up period maintained prophylaxis in a group of patients
with recurrent arrhythmia (22) .
Given this background . diltiazem would be expected to
reduce ventricular respon se in patients with atrial fibrilla-
tion. Thiesen et al. (41) noted a significant reduction in
mean ventricular rates after the short-term administration of
oral diltiazem and during oral maintenance therapy. Re-
cently, Roth et al. (42) found a significant improvement in
rest and exercise rate control when diltiazem was added to
digoxin in 12 patients with primarily rheumatic heart disease
and atrial fibrillation. Diltiazem therapy alone, particularly
at high dose s, produced adequate rate reduction as well. In
3 weeks of follow-up , the digoxin-diltiazem combination
also achieved significant rate reduction . Our study confirm s
and expands these preliminary findings with diltiazem. Dil-
tiazem -treated patients had moderate slowing of rest ven-
tricular response, and rates were sharply blunted at all stages
of submaximal exercise and at the peak of maximal exercise.
These results are consistent with diltiazem' s direct effect on
AV conduction.
Ambulatory electrocardiographic monitoring provides a
less artificial method for documenting drug efficacy. Dil-
tiazem was capable of maintaining a slower average rate in
the 24 hour period. The limits (maximal and minimal) of
ventricular rate similarly changed during therapy .
We could not document an overall improvement in max-
imal exercise time in our study group as a whole. This
failure to improve exercise capacity may be due to the ad-
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vanced age of our patients, which would impose unrelated
restraints on exercise. The majority of patients did report
subjective symptomatic improvement during the diltiazem
trial; however, these were unblinded observations.
Some investigators have found that reductions in heart
rate are proportional to basal rates (4,8,9) consistent with
the frequency dependence of calcium channel blockade (25)
in verapamil-treated patients or dependence of sympathetic
tone in beta-blocker-treated patients. We also found that
those patients with atrial fibrillation whose heart rate was
less than 90 beats/min at rest had much less slowing than
those with faster rates. Diltiazem, therefore, can be safely
added to the treatment regimen to prevent excess exercise
tachycardia even when rest ventricular response is slowed
with digoxin alone.
Previous studies of the interaction of diltiazem and di-
goxin have produced conflicting results showing either no
change (43,44) or an increase in digoxin levels (45-48).
The addition of diltiazem in our patients chronically treated
with digoxin produced no change in serum digoxin level,
thus confirming the safety of this combination therapy (40).
Adverse effects. These were more common than re-
ported in antianginal therapy trials (49). Undoubtedly this
is a consequence of the high doses of diltiazem used in the
study and the older age of our patients. The role of diltiazem
in the one patient with ventricular tachycardia remains un-
clear. All other described side effects were not serious and
could be reversed either spontaneously or with dose reduc-
tion or discontinuation of diltiazem. We found no incidence
of bradycardia or hypotension.
Limitations of study. This study was neither blinded
nor placebo controlled. Nonetheless, we carefully compared
the primary end point of ventricular response effects during
diltiazem therapy with periods both before and after treat-
ment and consistently documented excellent rate control on
drug therapy. Conclusions regarding symptomatic improve-
ment and exercise capacity are limited by the unblinded
format of the study. Our study does not answer whether
chronic therapy with diltiazem will show sustained efficacy.
Comparative efficacy of diltiazem to either digoxin alone
or verapamil was not assessed. Whether lower diltiazem
dosage will demonstrate efficacy with fewer adverse effects
is unknown. Though three patients in this study treated with
diltiazem alone had excellent results, this sample is too small
to allow recommendations to be made regarding diltiazem
as monotherapy.
Conclusion. Diltiazem is an effective agent for heart
rate control in patients with chronic atrial fibrillation treated
with concomitant digoxin. Symptoms were improved and
results were confirmed at rest, during various levels of ex-
ertion and during 24 hour ambulatory monitoring. Diltiazem
therapy had no effect on digoxin levels and was not asso-
ciated with serious adverse effects.
We express our gratitude to Sheila Berry for her able assistance in preparing
this manuscript. We acknowledge Marion Laboratories. Kansas City. Mis-
souri. for supplying diltiazem and performing the diltiazem assay.
References
I. Panidis IP. Morganroth J, Baessler C. Effectiveness and safety of oral
verapamil to control exercise-induced tachycardia in patients with
atrial fibrillation receiving digitalis. Am J Cardiol 1983;52:1197-201.
2. DiBianco R, Morganroth J. Freitag JA, et al. Effects of nadolol on
the spontaneous and exercise-provoked heart rate of patients with
chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart
J 1984;108:1121-7.
3. Beasley R, Smith DA, McHaffie DJ. Exercise heart rates at different
serum digoxin concentrations in patients with atrial fibrillation. Br
Med J 1985;290:9-11.
4. Klein HO. Pauzner H. DiSegni E. David D. Kaplinsky E. The ben-
eficial effects of verapamil in chronic atrial fibrillation. Arch Intern
Med 1979;139:747-9.
5. Lang R. Klein HO. Weiss E. et al. Superiority of oral verapamil
therapy to digoxin in treatment of chronic atrial fibrillation. Chest
1983;83:491-9.
6. Lang R. Klein HO. Di Segni E, et al. Verapamil improves exercise
capacity in chronic atrial fibrillation: double-blind crossover study.
Am Heart J 1983:105:820-5.
7. Schwartz 18. Keefe D. Kates RE. Kirstein E, Harrison DC. Acute
and chronic pharmacodynamic interaction of verapamil and digoxin
in atrial fibrillation. Circulation 1982;65:1163-70.
8. David D, Di Segni E, Klein HO. Kaplinsky E. Inefficacy of digitalis
in the control of heart rate in patients with chronic atrial fibrillation:
beneficial effect of an added beta adrenergic blocking agent. Am J
CardioI1979;44:1378-82.
9. Yahalom J, Klein HO. Kaplinsky E. Beta-adrenergic blockade as
adjunctive oral therapy in patients with chronic atrial fibrillation. Chest
1977;71:592-6.
10. Brown RW. Goble AJ. Effect of propranolol on exercise tolerance of
patients with atrial fibrillation. Br Med J 1969:2:279-80.
II. Mitchell LB. Schroeder JS, Mason JW. Comparative clinical electro-
physiologic effects of diltiazem. verapamil and nifedipine: a review.
Am J Cardiol 1982;49:629-35.
12. Antman EM. Stone PH. Muller JE. Braunwald E. Calcium channel
blocking agents in the treatment of cardiovascular disorders. Part II:
Basic and clinical electrophysiologic effects. Ann Intern Med
1980:93:875-85.
13. Lathrop DA. Valle-Aquilera JR. Millard RW. et al. Comparative
electrophysiologic and coronary hemodynamic effects of diltiazem,
nisoldipine and verapamil on myocardial tissue. Am J Cardiol
1982;49:613-20.
14. Kawai C. Konishi T. Matsuyama E. Okazaki H. Comparative effects
of three calcium antagonists. diltiazern. verapamil and nifedipine, on
the sinoatrial and atrioventricular nodes. Circulation 1981;63:1035-42.
15. Rinkenberger RI., Prystowsky EN. Heger JJ. Troup PJ. Jackman WM.
Zipes DP. Effects of intravenous and oral verapamil administration in
patients with supraventricular tachyarrhythmias. Circulation
1980;62:996-1010.
16. Sung RJ. Elser B. McAllister RG. Intravenous verapamil for termi-
nation of re-entrant supraventricular tachycardias. Ann Intern Med
1980:93:682-9.
17. Stem EH, Pitchon R. King BK. Guerrero J. Schnider RR. Weiner I.
Clinical use of oral verapamil in chronic and paroxysmal atrial fi-
brillation. Chest 1982;81:308-11.
18. Smith MS. Verghese CP. Shand DG. Pritchett ELC. Pharmacokinetic
JACC Vol. 9. No. 2
February 1987:405-11
STEINBERG Ei AL.
DlLTIAZEM FOR ATRIAL F[BRILLATION
411
and pharmacody namic effec ts of diltiazem. Am J Cardiol
1983:5 1:1369- 74 .
19. Ritterman JB. Hossack KF. Bruce RA. Acute and chronic effects of
diltiazem on A-V conduction at rest and during exercise . J Electro-
cardioI 1982:15:4 1- 6.
20 . Rozanski JJ , Zarman L, Castellanos A. Electrophysio logic effects of
dilt iazem hydrochloride on supraventricular tachycardia. Am J Cardiol
1982:49:621- 8.
21. Betr iu A, Chaitman BR. Bourassa MG. et al. Beneficial effect of
intravenous diltiazem in the acute management of paroxysmal supra-
ventricular tachyarrhythmias. Circulation 1983:67:88- 94 .
22. Yeh S. Kou H. Lin F. Hung J , Wu D. Effects of oral dilt iazem in
paroxysmal supraventricular tachycardia. Am J Cardiol 1983:52:271-8 .
23. Spodick DH. First and second versus second and third exercise tests.
Circulation 1975:51 :394.
24 . Rosen MR , Wit AW, Hoffman BF. Electrophysiology and pharma-
cology of cardiac arrhythmias. VI. Cardiac effects of verapamil. Am
Heart J 1975:89:665-73.
25 . Wit AW. Cranefield PF. Effect of verapamil on the sinoatrial and
atriove ntricular nodes of the rabbit and the mechanism by which it
arres ts reentrant atriovent ricular nodal tachycardia. Circ Res
1974 ;35:413- 25.
26. Klein HO. Kaplinsky E. Verapamil and digoxin: their respect ive ef-
fects on atrial fibrillation and their interaction. Am J Cardiol
1982:50:894- 902.
27 . Schwartz JB. Verapamil in atrial fibrillation: the expected. the un-
expec ted. and the unknown. Am Heart J 1983:106:17 3-6.
28 . Maniardi LM. Hariman RJ. McAll ister RG. Bhargam V. Surawicz
B, Shabetai R. Electrophysiologic and hemodynamic effects of vc-
rapamil. Circulation 1978:57:366- 72.
29. Lewis BS, Mitha AS. Gotsman MS. Immediate haemodynamic effec ts
of verapa mil in man. Cardiology 1975:60:366- 76 .
30. Pederson KE, Dorph-Pederson A. Hvidt S. Klitgaard NA, Pederson
KK. The long-term effec t of verapamil on plasma digoxin concent ra-
tion and renal digoxin clearance in healthy subjects . Eur J Clin Phar-
macol 1982:22:123-7.
31. Klein HO, Lang R, Weiss E. et al. The influence of verapamil on
serum digoxin concentration . Circulation 1982:65:998-1003.
32 . Belz GG . Doering W, Munkes R. Matthews J. Interaction between
digoxin and calcium antagonists and antiarrhythmic drugs. Clin Phar-
macol Ther 1983:33:410-7.
33. Schwartz JB. Keefe DL. Kirsten E, Kates RE. Harrison DC. Prolon-
gation of verapamil el imination kinetics during chronic oral admin-
istration. Am Heart J 1982:104:198- 203.
34. Khalsa A. Olsson SB . Verapamil-induced ventricu lar regularity in
atrial fibrillation. Acta Med Scand 1979:205:509- 15.
35. Schwartz JB. Nielsen AP. Griffin Jc. Concentration-dependent en-
hancement of junctional pacemaker activity by verapamil in man.
Circulation 1985:71:450-7.
36 . Urquhart J . Patterson RE, Bacharach SL. et al. Comparative effec ts
of verapamil, diltiazem . and nifedipine on hemodynamics and left
ventricular function during acute myocardial ischemia in dogs. Cir-
culation 1984:69:382-90 .
37. Walsh RA. Badke FR. O'R ourke RA. Differential effects of syste mic
and intracoro nary calcium channel blocking agents on global and re-
gional left ventricular function in conscious dogs. Am Heart J
1981:102:34 [- 50 .
38. Nakaya H. Schwartz A. Millard RW. Reflex chronotropic and ino-
tropic effects of calcium-channel blocking agents in conscious dogs .
Circ Res 1983:52:302-11 .
39. Walsh RW. Porter CB . Starling MR. O' Rourke RA. Benefic ial hemo-
dynamic effects of intravenous and oral diltiazem in severe conge stive
heart failure . J Am Coli Cardiol 1984;3:1044-50.
40 . Mitchell LB. Jutzy KR, Lewis SJ. Schroeder JS. Mason JW . Intra-
cardiac electrophysiologic study of intravenous diltiazem and com-
bined diltiazem-digoxin in patients. Am Heart J 1982:103:57-66 .
4 1. Thiesen K. Haufe M. Peters J. Thiesen F. Jahrmarker H. Effect of
the calcium antagonist diltiazem on atrioventricular conduction in chronic
atria l fibrillation. Am J Cardio l 1985:55:98- 102.
42 . Roth A. Harrison E. Mitani G. Cohen J, Rahimtoola S. Elkayam U.
Efficacy and safety of medium- and high-dose di ltiazern alone and in
combination with digoxi n for control of heart rate at rest and dur ing
exercise in patients with chronic atrial fibrillation. Circulation
1986:73:316- 24.
43 . Elkayam U. Parikh K. Torkan B. Weber L, Cohen J. Rahimtoola S.
Effect of diltiazem on renal clearance and serum concentration of
digoxin in patients with cardiac disease. Am J Cardiol 1985:55:1393- 5.
44 . Beltrami TR, May JJ. Bertino JS. Lack of effects of dilt iazem on
digoxi n pharmacokinetics. J Clin Pharmaco l 1985:25:390-2.
45 . Oyama Y. Fuj ii S. Kanda K. et al. Digoxin-diltiazem interaction . Am
J Cardiol 1984:53:1480- 1.
46 . Rameis H. Magometschnigg D. Ganzinger U. The diltiazem-d igoxin
interaction. Clin Pharmacol Ther 1984:36:182- 9.
47 . Yashida A. Fujita M. Kurosawa N. et al. Effects of diltiazem on
plasma level and urinary excretion of digoxin in healthy subjects . Clin
Pharmacol Ther 1984:35:681-5 .
48. Kuhlmann J. Effects of nifedipine and diltiazem on plasma levels and
renal excretion of beta-acetyldigoxin. Clin Pharmac ol Ther
1985;37: 150-6 .
49 . Hossack Kl-, Pool EP, Steele P. et al. Efficacy of diltiazem in angina
on effort : a multicenter trial. Am J Cardio l 1982:49:567-72 .
